Clinical Developments of the Tumor Suppressor p53
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 1740
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue, "Clinical Developments of the Tumor Suppressor p53", will mainly focus on the most promising advancements in clinical research on how p53 and its mutations impact patients in the clinic and on the novel drugs currently advancing to clinical trials to treat this once “undruggable” target.
TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutations, wild-type (WT) p53 is inactivated through interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alteration in cancer, p53 is an attractive target for the development of new targeted therapies for this disease.
We invite authors to submit original research and review articles that focus on the biological functions and therapeutic potential of the p53 pathway. Potential topics include, but are not limited to, the following:
- P53 targeted therapies;
- MDM2/4 targeted therapies;
- Role of p53 in drug resistance;
- Role of p53 in secondary cancers;
- Therapeutic options for Li–Fraumeni syndrome.
Dr. Naoise C. Synnott
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mutant p53
- TP53
- treatment
- targeting
- cancer
- MDM2
- MDM4
- LFS
